Core Insights - A new partnership has been established between MedicAlert Foundation, Sickle Cell Disease Association of America (SCDAA), and Fulcrum Therapeutics to enhance emergency care for individuals with sickle cell disease (SCD) during pain crises [1][3][5] Group 1: Partnership Objectives - The collaboration aims to streamline emergency department (ED) care by providing rapid access to patient-specific care plans, which is crucial during acute pain crises [1][2] - The initiative builds on a program launched in 2023 between MedicAlert and SCDAA, with Fulcrum's involvement expected to broaden outreach and empower more individuals with SCD [3][5] Group 2: Patient Care Enhancements - Participants will receive a MedicAlert Smart Medical ID Card linked to a secure digital health profile, allowing ED personnel to quickly access essential medical information, including pain management plans and contact details for healthcare providers [3][4] - The program addresses significant barriers faced by SCD patients in receiving timely and compassionate care during emergencies, aiming to reduce suffering and improve clinical decision-making [4][5] Group 3: Industry Context - SCD affects approximately 100,000 individuals in the U.S., highlighting the urgent need for improved care coordination and innovative solutions to meet the unmet needs of this patient population [4] - Fulcrum Therapeutics is focused on developing therapies for rare diseases, including SCD, and aims to enhance the overall care journey for patients through this partnership [5][6]

Fulcrum Therapeutics Conference Call Summary Company Overview - **Company**: Fulcrum Therapeutics (NasdaqGM: FULC) - **Focus**: Development of treatments for sickle cell disease, specifically the drug pociredir Key Industry Insights - **PIONEER Study Results**: The full data from the PIONEER study was recently announced, showing promising results in increasing fetal hemoglobin (HbF) levels in patients with sickle cell disease. The average HbF increased from 7.1% to 19.3%, a delta of 12.2% [3][4] - **Physician Feedback**: The physician community has responded positively to the data, particularly regarding the rapid induction of HbF and the reduction in hemolysis markers [3][4] - **Vaso-Occlusive Crises (VOCs)**: The study observed only 6 VOCs compared to the expected 16 over 12 weeks, with 7 out of 12 patients experiencing no VOCs during treatment [6][10] Clinical Data Highlights - **HbF Levels**: Almost 60% of patients achieved HbF levels of at least 20%, while all patients saw an increase of at least 6.5% [10][11] - **Patient Variability**: Some patients did not reach the 20% HbF mark, but even smaller increases were deemed clinically meaningful, potentially reducing hospital admissions [11] - **Geographic Factors**: Variability in patient responses may be influenced by geographic factors, particularly in patients from the Democratic Republic of Congo, who may have a specific haplotype associated with lower HbF levels [13][15] Regulatory and Development Plans - **FDA Engagement**: The company plans to propose a registrational study to the FDA, potentially using HbF as a surrogate endpoint for accelerated approval, with a focus on a severe patient population [21][23] - **Study Design**: The registrational study is expected to involve 200-300 patients, with an interim look at HbF levels at the six-month mark [23][24] - **EMA Engagement**: The company will engage with the European Medicines Agency (EMA) mid-year, aiming for harmonization in clinical development programs [29][30] Financial and Strategic Outlook - **Cash Runway**: Fulcrum Therapeutics has sufficient cash reserves to fund operations through 2029, focusing primarily on the sickle cell program [42] - **Future Aspirations**: The company aims to become a leading benign hematology company, exploring both internal discovery and potential in-licensing opportunities [43][44] - **DBA Program Discontinuation**: The company has decided to discontinue its DBA program to concentrate resources on the sickle cell initiative [47][48] Market Considerations - **Impact of Competitors**: The recent withdrawal of Ipsen's Tazverik has raised questions about the implications for pociredir, although the two drugs target different mechanisms [36][38][39] - **Partnership Potential**: While the company aims to commercialize pociredir in the U.S. independently, it may consider partnerships for international markets [40][41] Conclusion Fulcrum Therapeutics is positioned to advance its sickle cell treatment program with promising clinical data and a clear regulatory strategy, while also maintaining a focus on financial sustainability and future growth in benign hematology.

Company Overview - Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecules aimed at improving the lives of patients with genetically defined rare diseases [3] - The company's lead clinical program is pociredir, a small molecule designed to increase the expression of HbF for the treatment of sickle cell disease (SCD) [3] - Fulcrum employs proprietary technology to identify drug targets that can modulate gene expression, addressing the root cause of gene mis-expression [3] Upcoming Events - Company management will present at the Leerink Partners Global Healthcare Conference in Miami, FL on March 10, 2025, at 1:00 p.m. ET [1] - The presentation will be accessible via a webcast, which will also be available for replay on the company's website for at least 30 days following the event [2]

Financial Data and Key Metrics Changes - The 20 mg cohort of pociredir showed a mean absolute increase in fetal hemoglobin (HbF) of 12.2%, rising from a baseline of 7.1% to 19.3% at week 12 [9][15] - Total hemoglobin increased by more than 1 g/dL after 12 weeks of treatment [9][20] - The safety profile of pociredir at the 20 mg dose remains generally well-tolerated, with no treatment-related serious adverse events reported [21][80] Business Line Data and Key Metrics Changes - In the 20 mg cohort, 58% of patients achieved HbF levels at or above 20%, which is associated with clinically meaningful protection [9][15] - The cohort demonstrated a 34% reduction in lactate dehydrogenase (LDH) and a 40% reduction in indirect bilirubin, indicating reduced hemolysis [18] - A 42% drop in reticulocytes was observed, reflecting decreased bone marrow stress due to reduced hemolysis [19] Market Data and Key Metrics Changes - The unmet medical need for sickle cell disease treatments remains significant, with current options limited primarily to hydroxyurea [25][86] - The global sickle cell disease population is estimated at 7.7 million, with a substantial number in Sub-Saharan Africa [90] Company Strategy and Development Direction - The company plans to initiate a potential registration-enabling trial in the second half of 2026, pending feedback from the FDA [31] - Engagement with the European Medicines Agency is planned for mid-2026 to obtain protocol assistance [31] - The company aims to maintain a competitive edge in the market, believing it has a two-year head start over competitors [76] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential of pociredir to significantly reduce vaso-occlusive crises and hemolytic anemia in sickle cell disease patients [25][26] - The management highlighted the importance of advancing into a registration-enabling study due to the robust data generated [51][82] - There is a strong belief that if results are replicated in late-phase clinical trials, pociredir could serve as a first-line therapy for sickle cell disease [29] Other Important Information - The 20 mg cohort had no transfusions during the treatment period, contrasting with the 12 mg cohort [20] - The study design included a high degree of disease severity among participants, which is critical for understanding treatment efficacy [12] Q&A Session Summary Question: Can you provide insight into the VOC data and when they occurred? - VOCs were spread throughout the treatment period, with more occurring in patients with lower increases in HbF [35] Question: How well does the 20 mg cohort represent the broader sickle cell patient population? - The 20 mg cohort is believed to represent a middle slice of the global population, with more heterogeneity observed in patients from Nigeria compared to South Africa [36][38] Question: Which biomarkers might take longer to show a clearer dose response? - Markers of hemolysis, such as LDH and bilirubin, are expected to show changes over time as HbF levels increase [41][43] Question: How will the company approach the meeting with the FDA regarding the registrational trial? - The company plans to discuss the robust data and the biological relationship between HbF levels and clinical outcomes with the FDA [51][52] Question: What is the degree of unmet need in sickle cell disease? - The unmet need is significant, with hydroxyurea being the only established treatment showing sustained effects, and many patients still experiencing severe events [86]

Financial Data and Key Metrics Changes - The 20-milligram cohort of the phase 1b PIONEER trial showed a mean absolute increase in fetal hemoglobin (HbF) of 12.2%, rising from a baseline of 7.1% to 19.3% at week 12 [6][13] - Total hemoglobin increased by more than 1 gram per deciliter after 12 weeks of treatment [7][18] - A reduction of 34% in lactate dehydrogenase (LDH) and 40% in indirect bilirubin was observed, indicating decreased hemolysis [16] Business Line Data and Key Metrics Changes - The 20-milligram cohort demonstrated that over half of the patients achieved HbF levels at or above 20%, which is historically associated with clinically meaningful protection [6][8] - The cohort consisted of 12 evaluable patients, with 7 reporting no vaso-occlusive crises (VOCs) during the treatment period [7][19] Market Data and Key Metrics Changes - The unmet medical need for sickle cell disease treatments remains significant, with mortality rates elevated and life expectancy reduced despite advances in clinical care [9] - The 20-milligram cohort included patients from Nigeria, reflecting a more heterogeneous population compared to previous cohorts [37] Company Strategy and Development Direction - The company plans to provide an update on the next trial design in Q2 2026 and aims to initiate a potential registration-enabling trial in the second half of 2026 [30] - The strategy includes engaging with the European Medicines Agency for protocol assistance and feedback on the next trial [30] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential of pociredir to significantly reduce acute vaso-occlusive events and hemolytic anemia in sickle cell disease patients [24][29] - The company believes it has a two-year head start over competitors in the market for fetal hemoglobin-inducing agents [76] Other Important Information - Pociredir continues to be generally well-tolerated at the 20-milligram dose, with no treatment-related serious adverse events reported [19][20] - The company has dosed almost 150 adults to date, with no dose-limiting toxicities observed [20] Q&A Session Summary Question: Can you provide additional insight into the VOCs and when they occurred during the study? - VOCs were spread throughout the treatment period, with more occurring in patients with lower increases in HbF [34] Question: How well does the 20-milligram cohort represent the population of sickle cell patients? - The cohort is likely more representative of the global population, with a more heterogeneous haplotype distribution [37] Question: Which biomarkers might take longer to show a clearer dose response? - Markers of hemolysis, such as LDH and bilirubin, may take longer to reflect the full effects of HbF induction [41][44] Question: How will the company approach the meeting with the FDA regarding the registrational trial? - The company plans to discuss the robust data supporting HbF induction and its association with improved clinical outcomes [50] Question: What is the degree of unmet need in sickle cell disease? - The unmet need is significant, with hydroxyurea being the only established treatment, and many patients continue to experience severe events despite treatment [85]

Financial Data and Key Metrics Changes - The 20-milligram cohort of the PIONEER trial showed a mean absolute increase in fetal hemoglobin (HbF) of 12.2%, rising from a baseline of 7.1% to 19.3% at week 12 [5][12] - Total hemoglobin increased by more than 1 gram per deciliter after 12 weeks of treatment [5][21] - The safety profile of pociredir at the 20-milligram dose remains generally well-tolerated, with no treatment-related serious adverse events reported [18][81] Business Line Data and Key Metrics Changes - In the 20-milligram cohort, 58% of patients achieved HbF levels at or above 20%, which is historically associated with clinically meaningful protection [5][12] - There was a 34% reduction in lactate dehydrogenase (LDH) and a 40% reduction in indirect bilirubin at week 12, indicating reduced hemolysis [15] - The cohort experienced a 42% drop in reticulocytes, reflecting decreased bone marrow stress due to reduced hemolysis [16] Market Data and Key Metrics Changes - Sickle cell disease remains a debilitating condition affecting millions globally, with significant unmet medical needs despite advances in clinical care [7] - The expected vaso-occlusive crises (VOCs) based on baseline data was 16 events over 12 weeks, but only 6 events were observed in 5 patients during the treatment period [17] Company Strategy and Development Direction - The company plans to provide an update on the next trial design in Q2 2026 and aims to initiate a potential registration-enabling trial in the second half of 2026 [29] - Engagement with the European Medicines Agency is planned for mid-2026 to obtain protocol assistance and feedback on the next trial design [29] - The company is activating sites for an open-label extension study for PIONEER patients to evaluate the longer-term safety and durability of response of pociredir [29] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential of pociredir to significantly impact the treatment of sickle cell disease, especially given the limitations of current therapies like hydroxyurea [22][86] - The unmet need for effective treatments in sickle cell disease is highlighted, especially following the withdrawal of certain therapies and the limited uptake of others [86] - The company believes it has a two-year head start over competitors in the market for fetal hemoglobin-inducing agents [78] Other Important Information - The 20-milligram cohort data reinforces the belief that pociredir is demonstrating a biological profile expected from a best-in-class oral HbF inducer for sickle cell disease [6] - The trial design included a high degree of disease severity among participants, with a focus on patients with significant baseline VOCs [9] Q&A Session Summary Question: Can you provide additional insight into when VOCs occurred during the study? - VOCs were spread throughout the treatment period, with more occurring in patients with lower increases in HbF [32][34] Question: How well does the 20-milligram cohort represent the population of sickle cell patients? - The 20-milligram cohort is believed to represent a middle slice of the global population, with more heterogeneity in haplotypes compared to previous cohorts [35][37] Question: Which biomarkers might take longer to show a clearer dose response? - Markers of hemolysis, such as LDH and bilirubin, are expected to show more immediate effects, while total hemoglobin may take longer to reflect the full impact of HbF induction [40][44] Question: How will the company approach the meeting with the FDA regarding the registrational trial? - The company plans to discuss the robust data supporting HbF induction and its association with improved clinical outcomes in sickle cell disease [49][50] Question: What is the degree of unmet need in sickle cell disease? - The unmet need is significant, with hydroxyurea being the only established therapy showing sustained disease-modifying effects, and many patients still experiencing severe events [86]

Core Insights - Fulcrum Therapeutics announced positive 12-week results from the 20 mg dose cohort of the Phase 1b PIONEER trial for pociredir in sickle cell disease (SCD), showing a mean absolute HbF increase of 12.2% from a baseline of 7.1% to 19.3% at Week 12, along with improvements in hemolysis and anemia markers, and trends in vaso-occlusive crisis reduction [1][5][10] - The company plans to initiate a potential registration-enabling trial in the second half of 2026, following discussions with the FDA regarding the next study design [1][2][5] - As of December 31, 2025, Fulcrum had $352.3 million in cash, cash equivalents, and marketable securities, providing a cash runway into 2029 [1][8][15] Recent Business Highlights - The 20 mg cohort of the PIONEER trial included 12 participants and demonstrated significant HbF induction and safety, with no treatment-related serious adverse events reported [5][10] - Fulcrum completed a public offering in December 2025, raising $164.2 million in net proceeds, which bolstered its financial position for advancing pociredir and other corporate purposes [5][7] - The company has decided not to advance its program for bone marrow failure syndromes into clinical development, focusing resources on pociredir and its benign hematology pipeline [5][10] Financial Results - Research and development expenses for Q4 2025 were $15.4 million, up from $11.7 million in Q4 2024, primarily due to costs associated with the PIONEER trial [6][7] - General and administrative expenses for Q4 2025 were $7.3 million, a slight decrease from $7.7 million in Q4 2024, attributed to lower professional services costs [7] - The net loss for Q4 2025 was $20.3 million, compared to a net loss of $16.6 million in Q4 2024, while the annual net loss for 2025 was $74.9 million, significantly higher than the $9.7 million loss in 2024 [7][16]

Company Overview - Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, particularly in areas of high unmet medical need [4] - The company's lead clinical program is pociredir, designed to increase fetal hemoglobin expression for the treatment of sickle cell disease (SCD) [4] Clinical Development - Fulcrum will present 12-week results from the 20 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease on February 24, 2026 [1] - Pociredir is an investigational oral small-molecule inhibitor of Embryonic Ectoderm Development (EED), leading to downregulation of fetal globin repressors and increased fetal hemoglobin [5] - In the PIONEER trial, pociredir has shown dose-dependent increases in fetal hemoglobin, improvements in markers of hemolysis and anemia, and has been generally well-tolerated with no serious adverse events reported [5] Expert Involvement - Dr. Martin Steinberg, a prominent hematologist with extensive research on sickle cell disease, will join Fulcrum management for the conference call [2][3] - Dr. Steinberg has published over 450 articles and has contributed significantly to understanding the genetic basis and pathophysiology of sickle cell disease [3] Regulatory Status - Pociredir has received Fast Track and Orphan Drug Designation from the FDA for the treatment of sickle cell disease [5] Disease Background - Sickle cell disease is a genetic disorder caused by a mutation in the HBB gene, leading to inefficient oxygen transport and sickle-shaped red blood cells, which can cause various serious health complications [6]

Core Viewpoint - Fulcrum Therapeutics is focused on developing oral small molecules aimed at modifying gene expression for rare diseases, with a current emphasis on sickle cell disease and their lead asset, pociredir, which is a fetal hemoglobin inducer [4]. Group 1: Company Overview - Fulcrum Therapeutics is led by CEO Alex Sapir, who expressed gratitude for the support from JPMorgan and highlighted the quality of their recent report [2]. - The company’s strategic focus is on addressing high unmet needs in rare diseases, particularly in benign hematology [4]. Group 2: Product Focus - The lead product, pociredir, is designed to induce fetal hemoglobin, which is expected to be a best-in-class treatment for sickle cell disease [4].

Fulcrum Therapeutics Conference Call Summary Company Overview - **Company**: Fulcrum Therapeutics (NasdaqGM: FULC) - **Focus**: Development of oral small molecules to modify gene expression for rare diseases, specifically targeting sickle cell disease [1][2] Key Product Information - **Lead Asset**: Pociredir, a fetal hemoglobin inducer for sickle cell disease - **Regulatory Status**: Fast Track and Orphan designation, with patents extending to 2040 [2] - **Current Studies**: Wrapping up a Phase Ib study with plans for an end-of-phase meeting with regulatory agencies in the first half of 2026 [2][21] Financial Position - **Cash Runway**: $352 million at the end of the previous year, sufficient to fund operations through at least 2029 [3][23] Sickle Cell Disease Insights - **Prevalence**: Approximately 7.7 million people globally, with 100,000 in the U.S. and 55,000 in Europe [4] - **Impact**: Patients experience chronic pain and acute vaso-occlusive crises (VOCs), leading to significant hospitalizations and a reduction in life expectancy by over 20 years [5][6] Market Dynamics - **Recent Challenges**: Several treatments, including Adakveo and Oxbrita, have been withdrawn due to ineffectiveness, highlighting the high unmet need in sickle cell treatment [6][7] - **Current Treatment Landscape**: Includes anti-polymerization inhibitors and gene therapies, but these have limitations in patient access and effectiveness [8][9] Clinical Data Highlights - **Efficacy of Pociredir**: - Achieved a fetal hemoglobin (HbF) increase from 7% to 16.9% in the 20 mg cohort after six weeks [14][16] - 50% of patients reached HbF levels above 20%, which is associated with a significant reduction in VOCs [16][17] - Observed a reduction in VOCs from an expected 16 to only 5 during the study period [19][20] Safety Profile - **Adverse Events**: Treatment-related adverse events were generally mild, with no serious safety concerns reported [20][21] Future Milestones - **Upcoming Studies**: Plans to initiate a global registration study in the second half of 2026, with an open-label extension study for current participants [22][23] - **Regulatory Engagement**: Preparing for an end-of-phase meeting with the FDA to discuss trial design and endpoints [41][42] Conclusion - Fulcrum Therapeutics is positioned to address a significant unmet need in the treatment of sickle cell disease with its lead asset, pociredir. The company has a strong financial position and promising clinical data that support its potential for regulatory approval and market entry.